系统审查和元分析:木可以提高消除Helicobacter pylori的有效性
A Reum Choe1, Chung Hyun Tae1, Miyoung Choi2
1Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul, Korea.
Helicobacter
|October 10, 2024
概括
含石的疗法显著提高了Helicobacter pylori的根除率,特别是在高克拉里素耐药性地区. 这些方案提供了一个可行的选择,而不会增加副作用或抗生素耐药性.
科学领域:
- 胃肠病学 胃肠病学
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 毕斯穆特在 Helicobacter pylori 根除中的有效性尚未确定.
- 之前的研究对斯木的作用产生了不确定的结果.
研究的目的:
- 为了比较基于比斯木的与非比斯木根除方案对H. pylori的疗效.
- 分析不同方案的根除率,不良事件和药物合规性.
主要方法:
- 一个对13项随机对照试验的元分析,涉及2506名患者.
- 根据克拉里胺耐药性水平,树脂配方和剂量进行了子组分析.
主要成果:
- 与不含比斯木的疗法相比,含比斯木的疗法显示出更高的H. pylori根除率 (OR=1.63 ITT;OR=2.05 PP).
- 在高克拉里思罗米辛耐药性区域,疗效特别增强.
- 在药物适应性或不良事件中没有观察到显著差异.
结论:
- 在H. pylori根除方案中加入石可以提高成功率,尤其是在高克拉里素耐药性环境中.
- 石提供了一种有价值的治疗选择,具有有利的安全性和合规性,减轻了抗生素耐药性的担忧.
相关概念视频
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
328
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
328
Peptic Ulcer Disease IV: Management
74
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
74
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
94
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
94
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
409
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
409
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
356
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
356
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
360
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
360


